Single-Dose Syphilis Treatment: A Potential Game-Changer Amidst Ongoing Drug Shortages
Syphilis rates are climbing in the US, and access to treatment isn’t always easy. Recent findings offer a promising solution: a new study suggests a single injection of benzathine penicillin G (BPG) - sold under the brand name Bicillin L-A – may be just as effective as the standard three-dose regimen for early-stage syphilis. This is notably meaningful given the recurring shortages of this crucial antibiotic.
Understanding the Rising Threat of Syphilis
Syphilis is a bacterial infection spread through direct contact with a syphilis sore, often during sexual activity. While treatable with antibiotics, ignoring it can lead to serious health problems, impacting the brain, heart, and nervous system. The numbers are concerning. In 2023, the US saw over 209,000 cases – a staggering 61% increase as 2019.
Even more alarming is the surge in congenital syphilis – infection passed from mother to baby during pregnancy. Cases jumped a dramatic 108% between 2019 and 2023,reaching 3,882. Congenital syphilis can have devastating consequences, including miscarriage, stillbirth, and lifelong health issues for the infant.
The Challenge of Treatment Access
Currently, the standard treatment for early-stage syphilis involves three intramuscular injections of BPG, administered a week apart. This multi-dose requirement presents a significant hurdle. It necessitates multiple healthcare visits,which can be difficult for individuals facing logistical challenges,stigma,or simply busy schedules. Missed follow-up appointments can lead to incomplete treatment and continued spread of the infection.
New Research Offers Hope
A recent late-stage clinical trial, funded by the National Institutes of Health (NIH), investigated whether a single BPG injection could be a viable choice. Researchers randomly assigned 249 participants with early-stage syphilis to receive either one injection or the traditional three.
The results? Six months after treatment, 76% of the single-dose group showed triumphant treatment outcomes, compared to 70% in the three-dose group. Importantly, this difference wasn’t statistically significant, meaning the single dose performed at least and also the standard regimen.
“Benzathine penicillin G is highly effective against syphilis, but the three-dose regimen can be burdensome and deter people from attending follow-up visits,” explains Dr. Carolyn Deal, Chief of the NIH’s enteric and Sexually Transmitted Infections Branch. “These new findings offer welcome evidence for potentially simplifying treatment with an equally effective one-dose regimen.”
The BPG Shortage Crisis
The timing of this research is critical. The US has experienced ongoing shortages of BPG/Bicillin L-A for the past two decades, including a nearly five-year stretch. Just as supply began to recover from a recent two-year shortage in July 2025, Pfizer recalled certain lots due to potential contamination. Currently, the US is relying on imports from other countries to address the national shortfall.
A single-dose treatment could considerably stretch the available supply, ensuring more people have access to the care they need.
What Does This Mean for the Future?
While these findings are encouraging, further research is essential to confirm the long-term efficacy and safety of a single-dose BPG regimen. Though, the potential benefits are clear:
Improved Patient Adherence: A single injection simplifies treatment, making it easier for individuals to complete the full course.
Reduced Burden on Healthcare Systems: Fewer appointments mean less strain on clinics and healthcare providers.
Optimized Drug Supply: A single-dose approach could maximize the impact of limited BPG supplies.
if implemented, this shift in treatment protocol could be a pivotal step in controlling the rising tide of syphilis and protecting both individuals and future generations.
Resources:
American sexual Health Association - Syphilis
American Sexual Health Association – Syphilis and Pregnancy
[American Sexual Health association – STI Epidemic Data](https://www.ashasexualhealth.org/cautious-optimism-as-new-2023-data-suggest
Worth a look